GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Cyclically Adjusted Price-to-FCF

CytoDyn (STU:296) Cyclically Adjusted Price-to-FCF : (As of Oct. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CytoDyn Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CytoDyn's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Cyclically Adjusted Price-to-FCF Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoDyn Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CytoDyn's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CytoDyn's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytoDyn's Cyclically Adjusted Price-to-FCF falls into.



CytoDyn Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CytoDyn's Cyclically Adjusted FCF per Share for the quarter that ended in May. 2024 is calculated as:

For example, CytoDyn's adjusted Free Cash Flow per Share data for the three months ended in May. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of May. 2024 (Change)*Current CPI (May. 2024)
=-0.002/132.5091*132.5091
=-0.002

Current CPI (May. 2024) = 132.5091.

CytoDyn Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201408 -0.035 100.352 -0.046
201411 -0.038 99.635 -0.051
201502 -0.037 99.032 -0.050
201505 -0.061 100.333 -0.081
201508 -0.065 100.548 -0.086
201511 -0.036 100.135 -0.048
201602 -0.095 100.040 -0.126
201605 -0.038 101.355 -0.050
201608 -0.045 101.617 -0.059
201611 -0.031 101.829 -0.040
201702 -0.058 102.779 -0.075
201705 -0.043 103.256 -0.055
201708 -0.039 103.587 -0.050
201711 -0.032 104.072 -0.041
201802 -0.046 105.052 -0.058
201805 -0.028 106.148 -0.035
201808 -0.036 106.383 -0.045
201811 -0.058 106.338 -0.072
201902 -0.044 106.649 -0.055
201905 -0.027 108.048 -0.033
201908 -0.037 108.245 -0.045
201911 -0.016 108.519 -0.020
202002 -0.037 109.139 -0.045
202005 -0.054 108.175 -0.066
202008 -0.062 109.662 -0.075
202011 -0.030 109.793 -0.036
202102 -0.034 110.968 -0.041
202105 -0.048 113.576 -0.056
202108 -0.043 115.421 -0.049
202111 -0.038 117.269 -0.043
202202 -0.014 119.703 -0.015
202205 -0.008 123.323 -0.009
202208 -0.014 124.958 -0.015
202211 -0.005 125.607 -0.005
202302 -0.007 126.928 -0.007
202305 -0.003 128.314 -0.003
202308 -0.004 129.538 -0.004
202311 -0.002 129.548 -0.002
202402 -0.002 130.930 -0.002
202405 -0.002 132.509 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytoDyn  (STU:296) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CytoDyn Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CytoDyn's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn Business Description

Industry
Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines